Investment Thesis
Cyanotech exhibits deteriorating financial health with persistent operating losses, negative free cash flow, and weak liquidity despite modest revenue growth. The company is burning cash while struggling to maintain profitability, indicating fundamental operational challenges in its medicinal chemicals and botanical products business.
Strengths
- Positive revenue growth of 5.0% YoY shows market demand persistence
- Reasonable gross margin of 32.6% indicates production efficiency at unit level
- Moderate leverage with debt-to-equity ratio of 0.52x provides some financial flexibility
Risks
- Negative operating cash flow of -220K and free cash flow of -306K indicate unsustainable burn rate
- Critical liquidity concerns with current ratio of 1.00x and quick ratio of 0.30x; cash position of only 649K insufficient for ongoing operations
- Persistent net losses (-925K) and negative interest coverage of -1.6x suggest inability to service debt from operations
- Operating margin of -4.4% indicates core business is unprofitable despite gross margin strength, suggesting overhead burden and operational inefficiency
Key Metrics to Watch
- Operating cash flow trend - must turn positive to ensure viability
- Cash balance and runway - critical given current burn rate
- Operating margin improvement - path to profitability at EBITDA level
- Revenue growth sustainability - whether 5% growth can accelerate
Financial Metrics
Revenue
12.8M
Net Income
-925.0K
EPS (Diluted)
$-0.13
Free Cash Flow
-306.0K
Total Assets
24.0M
Cash
649.0K
Profitability Ratios
Gross Margin
32.6%
Operating Margin
-4.4%
Net Margin
-7.2%
ROE
-11.5%
ROA
-3.8%
FCF Margin
-2.4%
Balance Sheet & Liquidity
Current Ratio
1.00x
Quick Ratio
0.30x
Debt/Equity
0.52x
Debt/Assets
66.4%
Interest Coverage
-1.56x
Long-term Debt
4.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-23T07:58:11.862721 |
Data as of: 2025-09-30 |
Powered by Claude AI